A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
144actual
Sites
4
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-13 | actual | When the study began enrolling |
| Primary completion | 2025-02-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Biological: VXB-241 60 mcg (Low Dose)
- Biological: VXB-241 120 mcg (Medium Dose)
- Biological: VXB-241 240 mcg (Medium-high Dose)
- Biological: VXB-241 480 mcg (High Dose)
- Biological: VXB-241 240 mcg
- Other: Placebo
- Biological: Arexvy 120 mcg
Primary outcomes
what the primary-completion date above is the date OFProportion of Older Adult Participants With 1 or More Unsolicited AEs
measured 1 month after first IMP injection (Days 1 to 30)
Proportion of Older Adult Participants With 1 or More Solicited AEs
measured 7 days after first IMP injection (Days 1 to 8)
Geometric Mean Fold Increase (GMFI) of RSV-A, RSV-B, hMPV-A, and hMPV-B Serum Neutralizing Antibody Titers in Older Adults
measured Pre-injection baseline to 1 month (Day 30) after first IMP injection
Ratio of Dose-response Curves for GMFIs of RSV-A, RSV-B, hMPV-A and hMPV-B Serum Neutralizing Antibody Titers in Older Adults
measured Pre-injection baseline to 1 month (Day 30) after first IMP injection
Publications
- PMID 40674411 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed